Nature Biotechnology 24, 31 - 39 (2006)
doi:10.1038/nbt0106-31
The licensing of DNA patents by US academic institutions: an empirical surveyLori Pressman1, Richard Burgess2, Robert M Cook-Deegan3, Stephen J McCormack4, Io Nami-Wolk5, Melissa Soucy5
& LeRoy Walters61
Lori Pressman is a Consultant to the Kennedy Institute of Ethics, 4 Crawford St., Cambridge, Massachusetts 02139, USA
2
Richard Burgess is at IP Data Corporation, 2003 Old Mission Road, New Smyrna Beach, Florida 32162, USA
3
Robert M. Cook-Deegan is at the Institute for Genome Sciences & Policy, Duke University, Box 90141, Durham, North Carolina 27708-0141, USA
4
Stephen J. McCormack is at NeuroSystec Corporation, Alfred E. Mann Foundation for Biomedical Engineering, 25134 Rye Canyon Loop, Valencia, California 91355, USA
5
Io Nami-Wolk and Melissa Soucy are at the Joseph and Rose Kennedy Institute of Ethics, Georgetown University, Washington, DC 20057-1212, USA
6
LeRoy Walters is at the Kennedy Institute of Ethics and Georgetown University, Washington, DC 20057-1212, USA.
Correspondence should be addressed to LeRoy Walters waltersl@georgetown.edu A survey of technology transfer of DNA inventions at 19 top US research universities reveals consensus, diversity and flexibility in intellectual property management. Patent filing and license terms are influenced by intended uses of inventions, outside market interest and NIH guidelines.
|
